Hercules Capital, Inc. (HTGC) - Q2 2017 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2017. Hercules Capital, Inc. is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and a Regulated Investment Company (RIC). The Company focuses on providing senior secured loans to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors. As of June 30, 2017, the Company had 82.8 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2017 | Six Months Ended June 30, 2016 |
|---|---|---|
| Total Investment Income | $94.8 million | $82.5 million |
| Net Investment Income | $48.0 million | $43.5 million |
| Net Realized Gain (Loss) | $(2.5) million | $(4.4) million |
| Net Unrealized Appreciation (Depreciation) | $(17.9) million | $(15.2) million |
| Net Increase in Net Assets from Operations | $27.6 million | $23.8 million |
| Net Asset Value (NAV) per Share | $9.87 | $9.90 (Dec 31, 2016) |
| Total Assets | $1.59 billion | $1.46 billion (Dec 31, 2016) |
| Total Liabilities | $771.3 million | $676.3 million (Dec 31, 2016) |
| Cash and Cash Equivalents | $160.4 million | $13.0 million (Dec 31, 2016) |
| Weighted Average Debt Outstanding | $707.3 million | $595.7 million |
Material Changes vs. Prior Period
- Investment Income Growth: Total investment income increased 15% year-over-year (YoY) to $94.8 million, driven by higher recurring interest income and fee accelerations from early loan repayments.
- Debt Restructuring: The Company issued $230 million of 4.375% Convertible Notes due 2022 in January 2017. Proceeds were used to fully redeem the remaining $110.4 million of 2019 Notes in February 2017.
- Portfolio Composition: The portfolio value remained relatively stable at approximately $1.4 billion. The "Sustainable and Renewable Technology" sector decreased from 10.9% to 6.6% of the portfolio, while "Drug Discovery & Development" increased to 31.5%.
- Liquidity Position: Cash and cash equivalents surged to $160.4 million from $13.0 million at year-end 2016, primarily due to the issuance of Convertible Notes and strong operating cash flows ($67.6 million provided by operations).
- Realized Losses: Net realized losses narrowed to $2.5 million (vs. $4.4 million in 2016), though gross realized losses of $14.0 million were recorded, primarily from write-offs of warrant and equity investments.
Guidance, Outlook, and Risks
- Control Investments & Impairments: Significant unrealized depreciation ($53.2 million) was recorded on the control investment in Solar Spectrum Holdings LLC (formerly Sungevity, Inc.) following a bankruptcy conversion. Conversely, $48.8 million in prior period impairments were reversed on debt investments.
- Non-Accrual Status: Seven debt investments were on non-accrual status as of June 30, 2017, with a fair value of $3.6 million (down from $6.2 million at year-end 2016).
- Unfunded Commitments: The Company has $57.6 million in unfunded contractual commitments available at the request of portfolio companies and $70.0 million in non-binding term sheets.
- Dividends: The Board declared a distribution of $0.31 per share for the quarter, payable in August 2017. The Company intends to distribute 100% of spillover earnings from 2016 in 2017.
- Risks: Key risks include the valuation of Level 3 assets (private investments), the ability of portfolio companies to achieve liquidity events (IPOs/M&A), and interest rate sensitivity given the floating-rate nature of the debt portfolio.
Investor Verification Checklist
- Debt Conversion Impact: Verify the long-term recoverability of the equity position in Solar Spectrum Holdings LLC following the Sungevity bankruptcy conversion.
- Non-Accrual Trends: Monitor the seven debt investments on non-accrual status for potential further write-downs or recoveries.
- Capital Deployment: Assess the Company's ability to deploy the $160 million cash balance and $195 million in available credit facilities into new originations to maintain yield targets.
- Convertible Note Dilution: Review the terms of the $230 million 2022 Convertible Notes (conversion price ~$16.41) and their potential dilutive impact if the stock price rises significantly.
- Portfolio Concentration: Note that the top 10 portfolio companies represent 36.8% of the total portfolio fair value; monitor performance of these key holdings.